RxDoctor Payments Data

Chun Hung Hsuih, MD

Internal Medicine · Brooklyn, NYNPI 1063591832

Payments from drug & device makers

$1,640in general payments, 2019–2025

Across 95 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$357
  • Gilead$310
  • Amarin Pharma, Inc.$187
  • AstraZeneca$180
  • Merck$156
  • GSK$144
  • plus $306 from 10 others

What the payments were for

  • Food & beverage$1,57596%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,640 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$74,739
Medicare patients
50
Services billed
957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl837$386,822
Diclofenac Epolamine442$297,660
JardianceEmpagliflozin304$260,795
JanuviaSitagliptin Phosphate172$137,068
FarxigaDapagliflozin Propanediol131$100,002
RybelsusSemaglutide63$97,010
ProliaDenosumab57$96,171
EliquisApixaban88$68,709
LinzessLinaclotide113$65,810
RestasisCyclosporine62$56,672
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$49,152
JanumetSitagliptin Phos/Metformin Hcl51$40,650
VemlidyTenofovir Alafenamide23$37,024
Diclofenac Sodium167$36,792
TrulicityDulaglutide35$33,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$43$311,249361 claims
MerckJanuvia, Janumet, Belsomra$156$192,993258 claims
Novo NordiskRybelsus, Ozempic$67$123,58392 claims
AstraZenecaFarxiga, Nexium$180$108,992164 claims
AmgenProlia$357$96,17157 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$144$75,380130 claims
PfizerEliquis$28$68,70988 claims
GileadVemlidy$310$37,02423 claims
Lilly USA, LLCTrulicity$29$33,31335 claims
NovartisEntresto$17$28,63532 claims
Esperion Therapeutics, Inc.Nexletol$25$18,29633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →